Roche has unveiled compelling Phase 3 data from the FENtrepid trial for fenebrutinib, an oral BTK inhibitor. The brain-penetrating medication demonstrated significant efficacy in treating primary progressive multiple sclerosis (PPMS), positioning itself as a potential high-efficacy oral alternative to current intravenous treatments.
Comparative Efficacy and Clinical Metrics The FENtrepid study compared fenebrutinib against Ocrevus, the current gold standard and the only approved therapy for PPMS. The trial successfully met its primary objective, proving that fenebrutinib is non-inferior to Ocrevus in reducing the risk of disability progression at the 24-week mark.
Key clinical highlights include:
-
Upper Limb Function: A 26% improvement over Ocrevus as measured by the Nine-Hole Peg Test (9PHT).
-
Composite Measures: A 22% benefit observed in combined scores for disability status (EDSS) and upper limb function.
-
Targeted Mechanism: As a brain-penetrant agent, fenebrutinib directly addresses the progressive biology of the disease within the central nervous system.
Market Context and Regulatory Timeline Fenebrutinib’s success stands out in a competitive landscape where other BTK inhibitors from major rivals like Sanofi and Merck KGaA have either failed late-stage trials or faced regulatory setbacks.
Roche plans to submit regulatory filings for fenebrutinib in the coming weeks. If approved, this would represent the first major scientific breakthrough for the PPMS community in over ten years, providing patients with a potent oral treatment option that preserves independence and daily functioning.
Source: https://pharmaphorum.com/news/data-builds-roches-dominance-primary-progressive-ms